Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM study

Abstract : OBJECTIVE: To evaluate the effects of oral delayed-release dimethyl fumarate (DMF; also known as gastro-resistant DMF) on MRI lesion activity and load, atrophy, and magnetization transfer ratio (MTR) measures from the Comparator and an Oral Fumarate in Relapsing-Remitting Multiple Sclerosis (CONFIRM) study. METHODS: CONFIRM was a 2-year, placebo-controlled study of the efficacy and safety of DMF 240 mg twice (BID) or 3 times daily (TID) in 1,417 patients with relapsing-remitting multiple sclerosis (RRMS); subcutaneous glatiramer acetate 20 mg once daily was included as an active reference comparator. The number and volume of T2-hyperintense, T1-hypointense, and gadolinium-enhancing (Gd+) lesions, as well as whole brain volume and MTR, were assessed in 681 patients (MRI cohort). RESULTS: DMF BID and TID produced significant and consistent reductions vs placebo in the number of new or enlarging T2-hyperintense lesions and new nonenhancing T1-hypointense lesions after 1 and 2 years of treatment and in the number of Gd+ lesions at week 24, year 1, and year 2. Lesion volumes were also significantly reduced. Reductions in brain atrophy and MTR changes with DMF relative to placebo did not reach statistical significance. CONCLUSIONS: The robust effects on MRI active lesion counts and total lesion volume in patients with RRMS demonstrate the ability of DMF to exert beneficial effects on inflammatory lesion activity in multiple sclerosis, and support DMF therapy as a valuable new treatment option in RRMS. CLASSIFICATION OF EVIDENCE: This study provides Class I evidence of reduction in brain lesion number and volume, as assessed by MRI, over 2 years of delayed-release DMF treatment.
Liste complète des métadonnées

https://hal.umontpellier.fr/hal-02122571
Contributeur : Anthony Herrada <>
Soumis le : mardi 7 mai 2019 - 14:17:39
Dernière modification le : mardi 9 juillet 2019 - 16:36:12

Lien texte intégral

Identifiants

Collections

Citation

David Miller, Robert Fox, J Theodore Phillips, Michael Hutchinson, Eva Havrdova, et al.. Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM study. Neurology, American Academy of Neurology, 2015, 84 (11), pp.1145-1152. ⟨10.1212/WNL.0000000000001360⟩. ⟨hal-02122571⟩

Partager

Métriques

Consultations de la notice

66